合并免疫调节剂对常规治疗失败的克罗恩病或溃疡性结肠炎患者阿达木单抗药代动力学、疗效和安全性的影响
本文分析六项随机双盲安慰剂对照试验,比较阿达木单抗单药与联合免疫调节剂治疗常规治疗控制不佳的中重度克罗恩病或溃疡性结肠炎患者。结果显示各研究中两组缓解比例相似,第4或8周中位阿达木单抗浓度联合组数值上较高但未达显著,不良事件发生率相似。
要点
- 六项随机对照试验事后分析显示,联合免疫调节剂与阿达木单抗单药相比未带来疗效获益。
- 第4或8周中位阿达木单抗浓度联合治疗组数值上较高但未达统计学显著。
- 两种治疗方案的不良事件发生率和发生率相似。
核心结论
- 六项随机对照试验的事后分析表明,在常规治疗控制不佳的克罗恩病和溃疡性结肠炎患者中,免疫调节剂联合阿达木单抗治疗与阿达木单抗单药相比无疗效获益,两种治疗方案的安全性相当。
研究设计与样本
- 对六项随机、双盲、安慰剂对照试验的事后分析,纳入常规治疗控制不佳的中重度克罗恩病或溃疡性结肠炎患者。
- 阿达木单抗单药组:克罗恩病诱导n=245、维持n=185;溃疡性结肠炎诱导n=213、维持n=157。
- 联合治疗组:克罗恩病诱导n=139、维持n=139;溃疡性结肠炎诱导n=140、维持n=100;分组依据基线免疫调节剂使用情况。
主要发现
- 所有研究中,阿达木单抗单药与免疫调节剂联合治疗达到缓解的患者比例相似。
- 克罗恩病和溃疡性结肠炎研究中,第4或8周中位阿达木单抗浓度联合治疗组较单药组数值上较高但未达统计学显著。
- 阿达木单抗单药与联合治疗的不良事件发生率和发生率相似。
关键数值与推荐
- 克罗恩病缓解定义为CD活动指数<150。
- 溃疡性结肠炎缓解定义为Mayo评分≤2且无单项评分>1。
- 疗效报告基于各研究意向治疗人群。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adalimumab is approved for use in patients with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) who have not achieved disease control with conventional therapies including corticosteroids and/or immunomodulators (IMM). AIM: To analyse six studies that examined efficacy, pharmacokinetics and safety of combination IMM/adalimumab therapy, compared with adalimumab monotherapy in patients with inadequate disease control on conventional therapy. METHODS: Patients with moderate to severe CD or UC from randomised, double-blind, placebo-controlled trials were analysed. Adalimumab was added to background therapy; patients were categorised as receiving adalimumab monotherapy (CD induction, n = 245, maintenance, n = 185; UC induction, n = 213, maintenance, n = 157) or combination therapy (CD induction, n = 139, maintenance, n = 139; UC induction, n = 140, maintenance, n = 100) according to baseline immunomodulator use. Efficacy was reported for the intent-to-treat populations from each study, with remission defined as CD activity index <150 for CD and Mayo score ≤2 with no subscore >1 for UC. Safety was assessed via adverse events. RESULTS: The proportions of patients achieving remission were similar for adalimumab monotherapy and immunomodulator combination therapy in all studies. Median adalimumab concentrations at week 4 or 8 were numerically but not significantly higher with adalimumab combination therapy vs. monotherapy in the CD and UC studies respectively. Incidence and rate of adverse events was similar for adalimumab monotherapy and combination therapy. CONCLUSIONS: Post hoc analysis of six randomised, controlled trials demonstrated no efficacy benefits with immunomodulator/adalimumab combination therapy, compared with adalimumab monotherapy in CD and UC patients with inadequate disease control on conventional therapy; the safety of the two treatment approaches was comparable.
引用
- Colombel JF, Jharap B, Sandborn WJ, et al. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Aliment Pharmacol Ther. 2016. PMID: 27883215. doi:10.1111/apt.13838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。